Current Trends in Transplantation of Patients with Hematological Malignancies
Main Article Content
Abstract
Hematopoietic stem cell transplantation (HSCT) is widely used to treat hematological malignancies and nonmalignant hematological disorders. Many advances have been made in improving the success of bone marrow transplantation. However, lack of available matched related or matched sibling donors has posed a significant challenges to the availability and proper utilization of hematopoietic stem cell transplantation in patients with hematological malignancies. The rising availability of alternative donors, particularly haploidentical donors (HIDs), has propelled the rapid rise of allo-HSCT. The aim of this review is to highlight and evaluate the recent advances in the development of HSCT, focusing mainly on the selection of suitable hematopoietic stem cell donors, HID-HSCT and some current advances in the use of umbilical cord blood cells as an alternative graft source. Haplo-HSCT has shown a promising result and better outcomes due to the number of advantages, including a wide range of stem cell sources, increased GVL effects, improved immunologic reconstitution, and positive clinical outcomes. In the near future, haplo-HSCT is likely to be considered as a better option for patient donor selection particularly in AML patients while HLA matching is unlikely to be the most important factor in AML patient donor selection. In addition, the use of umbilical cord blood cells has shown a promising role as an alternative source of HSCT even with other available sources such as bone marrow and peripheral blood. Other transplantation procedures, such as T-cell depletion allografts, Post-transplant cyclophosphamide (PTCY), G-CSF-mobilized allografts, and antithymocyte globulin, have contributed to significant improvements in haplo-HSCT outcomes in recent decades.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Aldenhoven, M. and Kurtzberg, J. (2015). Cord blood is the optimal graft source for the treatment of pediatric patients with lysosomal storage diseases: clinical outcomes and future directions. Cytotherapy;17:765–774.
Algwaiz, G., Aljurf, M., Koh, M. et al. (2020). Real‑world issues and potential solutions in hematopoietic cell transplantation during the COVID‑19 pandemic: perspectives from the worldwide network for blood and marrow transplantation and center for international blood and marrow transplant research health services and international studies commit‑ tee. Biology of Blood and Marrow Transplantation;26:2181–2189.
Aljurf, M., Weisdorf, D., Alfraih, F. (2019). Challenges facing emerging alternate donor registries”. Bone Marrow Transplant; 54:1179–1188.
Anasetti, C., Beatty, P.G., Storb, R. et al. (1990). Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Human Immunology;29: 79–91.
Appelbaum, F.R. (2014). Indications for Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in the Genomic Era. American Society of Clinical Oncology Educational Book;34(3): e327-e332.
Aversa, F., Terenzi, A., Tabilio, A. et al. (2005). Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. Journal of Clinical Oncology;23(15): 3447–3454.
Aversa, F., Tabilio, A., Velardi, A. et al. (1994). Successful engraftment of T-cell-depleted haploidentical “threeloci” incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood;84(11):3948–3955.
Ayers, E.C., Li, S., Medeiros. L.J., et al. (2020). Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. Cancer; 126(2):293-303.
Bacigalupo, A., Dominietto, A., Ghiso, A. et al. (2015). Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update. Bone Marrow Transplantation;50(2):S37–39.
Ballen, K.K., Verter, F., Kurtzberg, J.et al. (2015). Umbilical cord blood donation: public or private? Bone Marrow Transplant; 50:1271–1278.
Balligand, L., Galambrun, C., Sirvent, A, et al. (2019). Single-unit versus doubleunit umbilical cord blood transplantation in children and young adults with residual leukemic disease. Biology of Blood and Marrow Transplantation;25:734-742.
Barker, J.N., Kurtzberg, J., Ballen, K. et al. (2017). Optimal practices in unrelated donor cord blood transplantation for hematologic malignancies. Biology of Blood and Marrow Transplantation;23:882–896.
Barker, J.N., Weisdorf, D.J., DeFor, T.E.et al. (2005). Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood; 105:1343–1347.
Barker, J.N., Weisdorf, D.J., Wagner, J.E. (2001). Creation of a double chimera after the transplantation of umbilical-cord blood from two partially matched unrelated donors. New England Journal of Medicine;344:1870-1871.
Baron, F., Ruggeri, A., Beohou, E, et al. (2017). Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT. Journal of Hematology and Oncology;10:128.
Bashey, A., Zhang, X., Sizemore, C.A. et al. (2013). T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. Journal of Clinical Oncology;31:1310–1316.
Bastida, J.M., Cabrero, M., Lopez-Godino, O. et al. (2015). Influence of donor age in allogeneic stem cell transplant outcome in acute myeloid leukemia and myelodisplastic syndrome. Leukemia Reserach;39:828–834. .
Bejar, R., Stevenson, K.E., Caughey, B. et al. (2014). Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. Journal of Clinical Oncolgy ; 32:2691–2698.
Bejar, R., Stevenson, K., Abdel-Wahab, O. et al. (2011). Clinical effect of point mutations in myelodysplastic syndromes. National England Journal of Medicine; 364:2496–2506.
Benjamin, R.J., McGurk, S., Ralston, M.S. et al. (1999). ABO incompatibility as an adverse risk factor for survival after allogeneic bone marrow transplantation. Transfusion;39:179–187.
Blume, K.G., Beutler, E., Bross, K.J. et al. (1980). Bone-marrow ablation and allogeneic marrow transplantation in acute leukemia. New England. Journal of Medicine;302:1041–1046.
Boelens, J.J., Aldenhoven, M., Purtill, D. et al. (2013). Outcomes of transplantation using various hematopoietic cell sources in children with hurler syndrome after myeloablative conditioning. Blood; 121:3981–3987.
Boitano, A.E., Wang, J., Romeo, R, et al. (2010). Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science;329:1345-1348.
Borowitz, M.J., Devidas, M., Hunger, S.P.et al. (2008). Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A Children’s Oncology Group study. Blood; 111: 5477–5485.
Broxmeyer, H.E., Lee, M.R., Hangoc, G. et al. (2011). Hematopoietic stem/progenitor cells, generation of induced pluripotent stem cells, and isolation of endothelial progenitors from 21- to 23.5-year cryopreserved cord blood. Blood;117:4773–4777.
Canaani, J., Savani, B.N., Labopin, M.et al. (2018). Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation. American Journal of Hematology;93:246–253.
Canaani, J., Savani, B.N., Labopin, M.et al. (2017). Impact of ABO incompatibility on patients’ outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT. Haematologica;102:1066–1074.
Cao, Y.G, He, Y., Zhang, S.D.et al. (2020). Conditioning regimen of 5‑day decitabine administration for allogeneic stem cell transplantation in patients with myelodysplastic syndrome and myeloproliferative neoplasms. Biology of Blood and Marrow Transplantation;26:285–291.
Cesaro, S., Crocchiolo, R., Tridello, G. et al. (2018). Comparable survival using a CMV-matched or a mismatched donor for CMV + patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT. Bone Marrow Transplantation;53:422–430.
Chang, Y.J., Wang, Y., Xu, L.P. et al. (2020). Haploidentical donor is preferred over matched sibling donor for pre‑transplantation MRD positive ALL: a phase 3 genetically randomized study. Journal of Hematology and Oncology. ;13:27.
Chang, Y.J., Wang, Y., Liu, Y.R. et al. (2017). Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre‑transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. Journal of Hematology and Oncology;10:134.
Chang, Y.J., Wang, Y., Mo, X.D. et al. (2017). Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoi‑ etic stem cell transplantation: Long‑term outcomes of a prospective ran,domized trial. Cancer;123:2881–2892.
Chang, Y.J., Zhao, X.Y., Xu, L.P. et al. (2015). Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets. Journal of Hematolology Oncology;8: 84.
Chemaly, R.F., Ullmann, A.J., Stoelben, S. et al. (2014). Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. New England Journal of Medicine;370:1781–1789.
Chute, J.P., Muramoto, G.G., Whitesides, J, et al. (2006). Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proceedings of the National Academy of Sciences USA;103: 11707-11712.
Cicuttini, F.M., Welch, K.L. and Boyd, AW. (1994). The effect of cytokines on CD34+ Rh-123high and low progenitor cells from human umbilical cord blood. Experimental Hematolology;22:1244-1251.
Ciurea, S.O., Al Malki, M.M., Nagler, A. et al. (2020). The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. Bone Marrow Transplantation; 55: 12-24.
Ciurea, S.O., Shah, M.V., Saliba, R.M. et al. (2018). Haploidentical transplantation for older patients with acute myeloid leukemia and myelodysplastic syndrome. Biology of Blood and Marrow Transplantation;24: 1232–1236.
Ciurea, S.O., Cao, K., Fernadez-Vina, M. et al. (2018). The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. Bone Marrow Transplant;53:521–534
Ciurea, S.O., Thall, P.F., Milton, D.R. et al. (2015). Complement-binding donor-specific anti-HLA antibodies and risk of primary graft failure in hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation;21:1392–1398.
Ciurea, S.O., Zhang, M.J, Bacigalupo, A.A.et al. (2015). Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood;126: 1033–1040.
Ciurea, S.O., de Lima, M., Cano, P. et al. (2009). High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation;88:1019–1024.
Cohen, S., Roy, J., Lachance, S, et al. (2020). Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study. Lancet Haematology;7:134-145.
Cornelissen, J.J., Blaise, D. (2016). Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood; 127:62–70.
Crocchiolo, R., Castagna, L., Furst, S.et al. (2016). The patient’s CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide. Bone Marrow Transplantation;51:1134–1136.
Cwynarski, K., van Biezen, A., de Wreede, L. et al. (2012). Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's Syndrome): a retrospective analysis from the Chronic Lymphocytic Leukemia Subcommittee of the Chronic Leukemia Working Party and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology ;30:2211–2217.
Deeg, H.J., Gooley, T.A., Flowers, M.E.et al. (2003). Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood;102:3912–3918.
Dehn, J., Spellman, S., Hurley, C.K. et al. (2019). Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from NMDP/CIBMTR. Blood; 134:924–934.
Delaney, C., Heimfeld, S., Brashem-Stein, C. et al. (2010). Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nature Medicine;16: 232–236.
de Lima, M., McNiece, I., Robinson, S.N. et al. (2012). Cord-blood engraftment with ex vivo mesenchymal-cell coculture. New England Journal of Medicine;367:2305–2315.
de Lima, M., McMannis, J., Gee, A. et al. (2008). Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplantation;41:771–778.
Diorio, C. and Maude, S.L. (2020). CAR T cells vs. allogeneic HSCT for poor-risk ALL. Hematol. American Society of Hematology Education Program 2020;501–507.
Di Stasi, A., Milton, D.R., Poon, L.M. et al. (2014). Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. Biology of Blood and Marrow Transplantation;20:1975–1981.
Dreger, P., Ghia, P., Schetelig, J. et al. (2018). High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. Blood;132:892–902.
Dreger, P., Schetelig, J., Andersen, N. et al (2014). European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT). Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? Blood;124(26): 3841-3849.
Druker, B.J., Guilhot, F., O’Brien, S.G. et al. (2006). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine;355:2408-2417.
Duarte, R.F., Labopin, M., Bader, P. et al. (2019). Indication for haematopoietic stem cell transplantation for haematological diseases, solid tumors and immune disorders: current practice in europe: the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation; 54: 1525-1552.
Duarte, R.F., Boumendil, A., Onida, F. et al. (2014). Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and sézary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis. Journal of Clinical Oncology;32: 3347–3348.
Duarte, R.F, Canals, C., Onida, F. et al. (2010). Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology;28: 4492–4499.
Duarte, R.F., Schmitz, N., Servitje, O. et al. (2008). Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplant ;41:597–604.
Ebens, C.L., DeFor, T.E., Tryon, R. et al. (2018). Comparable outcomes after HLA-matched sibling and alternative donor hematopoietic cell transplantation for children with fanconi anemia and severe aplastic anemia. Biology of Blood and Marrow Transplantation; 24:765–771.
Eisner, M.D. and August, C.S. (1995). Impact of donor and recipient characteristics on the development of acute and chronic graft-versushost disease following pediatric bone marrow transplantation. Bone Marrow Transplantation;15: 663–668.
Elmariah, H., Kasamon, Y.L., Zahurak, M. et al. (2018). Haploidentical bone marrow transplantation with post-transplant cyclophosphamide using non-first-degree related donors. Biology of Blood and Marrow Transplantation;24:1099–1102.
Fares, I., Chagraoui, J., Gareau, Y, et al. (2014). Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal. Science.;345:1509-1512.
Figueroa, E., Villanueva-Toledo, J., Garrido, E. et al. (2011). In vitro effects of stromal cells expressing different levels of Jagged-1 and Delta-1 on the growth of primitive and intermediate CD34+ cell subsets from human cord blood. Blood Cells, Molecules and Diseases;47:205-213.
Frassoni, F., Labopin, M., Gluckman, E. et al. (1996). Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time–a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT). Bone Marrow Transplantation;17:13–18.
Fuchs, E.J. (2012). Haploidentical transplantation for hematologic malignancies: where do we stand? Hematology American Society of Hematology Education Programme;2012:230–236.
Ghosh, N., Karmali, R., Rocha, V.et al. (2016). Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: A Center for International Blood and Marrow Transplant Research Analysis. Journal of Clinical Oncology; 34:3141–3149.
Giebel, S., Czyz, A., Ottmann, O. et al. (2016). Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer; 122:2941–2951.
Gluckman, E., Broxmeyer, H.A., Auerbach, A.D. et al. (1989). Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. New England Journal of Medicine; 321:1174–1178. 34/ 83.
Goldman, J., Liesveld, J., Nichols, D. et al. (2003). ABO incompatibility between donor and recipient and clinical outcomes in allogeneic stem cell transplantation. Leukemia Research.;27:489–491.
Gonzalez-Vicent, M., Molina, B., Deltoro, N.et al. (2017). Donor age matters in T-cell depleted haploidentical hematopoietic stem cell transplantation in pediatric patients: faster immune reconstitution using younger donors. Leukemia Research;57: 60–64.
Guglielmelli, P., Lasho, T.L., Rotunno, G.et al. (2018). MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. Journal of Clinical Oncology;36:310–318.
Guo, H., Chang, Y-J., Huang, X-J. et al. (2021). Dynamic immune profiling identifies the stronger graft-versusleukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation. Cellular and Moleculer Immunology;18:1172–1185.
Hallek, M., Cheson, B.D., Catovsky, D. et al (2008). International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood;111(12): 5446-5456.
Hochhaus, A., O’Brien, S.G., Guilhot, F.et al. (2009). Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia ;23:1054-1061.
Horan, J., Wang, T., Haagenson, M. et al. (2012). Spellman SR, Dehn J, Eapen M, et al. Evaluation of HLA matching in unrelated hematopoietic stem cell transplantation for nonmalignant disorders. Blood; 24.
Huo, M.R., Pei, X.Y., Li, D. et al. (2018). Impact of HLA allele mismatch at HLA-A, -B, -C, -DRB1, and -DQB1 on outcomes in haploidentical stem cell transplantation. Bone Marrow Transplantation;53:600–608.
Horwitz, M.E., Wease, S., Blackwell, B, et al. (2019). Phase I/II study of stemcell transplantation using a single cord blood unit expanded ex vivo with nicotinamide. Journal of Clinical Oncology;37: 367-374.
Horwitz, M.E., Chao, N.J, Rizzieri, D.A, et al. (2014). Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. Journal of Clinical Investigation;124: 3121-3128.
Hough, R., Danby, R., Russell, N. et al. (2016). Marks Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols. British Journal of Haematology; 172:360–370.
Hsu, J., Artz, A., Mayer, S.A. et al. (2018). Combined haploidentical and umbilical cord blood allogeneic stem cell transplantation for high-risk lymphoma and chronic lymphoblastic leukemia. Biology of Blood and Marrow Transplantation;24: 359–365.
Hu, L.J.(2020). NK cell reconstitution following unmanipulated HLA-mismatched/ haploidentical transplantation compared with matched sibling transplantation. Science China Life Science;63:781–784.
Jain, T., Mesa, R.A., Palmer, J.M. (2017). Allogeneic stem cell transplantation in myelofibrosis. Biology of Blood and Marrow Transplantation;23:1429–1436.
Jaiswal, S., Fontanillas, P., Flannick, J. et al. (2014). Age-related clonal hematopoiesis associated with adverse outcomes. New England Journal of Medicine;371:2488–2498.
Jaroscak, J., Goltry, K., Smith, A, et al. (2003). Augmentation of umbilical cord blood (UCB) transplantation with ex vivo-expanded UCB cells: results of a phase I trial using the AastromReplicell System. Blood;101:5061-5067.
Jawed, S.I., Myskowski, P.L., Horwitz, S. et al. (2014). Primary cutaneous T-cell lymphoma (mycosis fungoides andSézary syndrome): part II. Prognosis, management, and future directions. Journal of American Academy of Dermatology;70: 223.e1–17.
Kanakry, C. G., de Lima, M. J. and Luznik, L. (2015). Alternative donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Semininars in Hematology. 52, 232–242.
Kanate, A.S., Majhail, N.S., Savani, B.N. et al. (2020). Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy: Guidelines for Hematopoietic Transplantation and Cellular Therapy. Biology Blood Marrow Transplant;
Kanda, J., Ichinohe, T., Matsuo, K. et al. (2009). Impact of ABO mismatching on the outcomes of allogeneic related and unrelated blood and marrow stem cell transplantations for hematologic malignancies: IPD-based metaanalysis of cohort studies. Transfusion;49:624–635.
Kasamon, Y.L., Luznik, L., Leffell, M.S. et al. (2010). Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biology of Blood and Marrow Transplantation;16:482–489.
Kawase, T., Morishima, Y., Matsuo, K. et al. (2007). High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood;110:2235–2241.
Khaddour, k., Hana, C.K., Mewawalla, P. et al. (2021). Haematopoietic Stem Cell Transplantation.
Kindwall-Keller, T.L. and Ballen, K.K. (2020). Umbilical cord blood: the promise and the uncertainty. Stem Cells Translational Medicine;9:1153-1162.
Kindwall-Keller, T.L., Hegerfeldt, Y., Meyerson, H.J, et al. (2012). Prospective study of one- vs two-unit umbilical cord blood transplantation following reduced intensity conditioning in adults with hematological malignancies. Bone Marrow Transplantation;47:924-933.
Kollman, C., Howe, C.W., Anasetti, C.et al. (2001). Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood;98: 2043–2051.
Kolb, H.J., Schmid, C., Barrett, A. J. et al. (2004). Graft-versus-leukemia reactions in allogeneic chimeras. Blood;103:767–776.
Kongtim, P., Di Stasi, A., Rondon, G. et al. (2015). Can a female donor for a male recipient decrease the relapse rate for patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation? Biology of Blood and Marrow Transplantation. ;21:713–719.
Kröger, N. (2012). Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome. Blood; 119:5632–5639.
Kröger, N., Zabelina, T., van Biezen, A. et al. (2011). Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis. Haematologica ; 96:291–297.
Kwon, M., Bautista, G., Balsalobre, P. et al. (2014). Haplo-cord transplantation using CD34+ cells from a third-party donor to speed engraftment in high-risk patients with hematologic disorders. Biology of Blood Marrow and Transplantation; 20:2015–2022.
Leung, W., Iyengar, R., Turner, V.et al. (2004). Determinants of antileukemia effects of allogeneic NK cells. Journal of Immunology;172:644–650.
Li, S.Q., Fan, Q.Z., Xu, L.P. et al. (2020). Different effects of pre‑transplantation measur‑ able residual disease on outcomes according to transplant modality in patients with philadelphia chromosome positive ALL. Frontiers in Oncology;10: 320.
Iida, M., Kodera, Y., Dodds, A. et al. (2019). Advances in hematopoietic stem cell transplantation in the Asia-Pacific region: the second report from APBMT 2005-2015. Bone Marrow Transplant; 54:1973–1986.
Linch, D.C., Winfield, D., Goldstone, A.H. et al. (1993). Dose intensification with autologous bonemarrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet;341:1051–1054.
Liu, H., Rich, E.S., Godley, L.et al. (2011). Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. (2011) 118:6438–6445.
Ljungman, P., Brand, R., Hoek, J. et al. (2014). Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation. Clinical Infectious Disease;59: 473–481.
Logan, A.C., Wang, Z., Alimoghaddam, K.et al. (2015). ABO mismatch is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation;21:746–754.
Lorentino, F., Labopin, M., Bernardi, M.et al. (2018). Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission. American Journal of Hematology;93:1236–1244.
Lorentino, F., Labopin, M., Fleischhauer, K. et al. (2017). The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis. Blood Advances;1: 669–680.
Lu, D.P., Dong, L.,Wu, T. et al. (2006). Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 107, 3065–3073.
Luznik, L., O’Donnell, P.V, Symons, H.J.et al. (2008). HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biology of Blood and Marrow Transplantation;14:641–650.
Ma, Y.R., Zhang, X., Xu, L. et al. (2021).G‑CSF‑primed peripheral blood stem cell haploidentical transplantation could achieve satisfactory clinical outcomes for acute leukemia patients in the first complete remission: a registered study. Frontiers in Oncology;11:631625.
Majhail, N.S., Brunstein, C.G., Wagner, J.E. (2006). Double umbilical cord blood transplantation. Current Opinion in Immunology.18 (5):571-575.
Mallhi, K.K., Smith, A.R., DeFor, T.E.et al. (2017). Allele-Level HLA matching impacts key outcomes following umbilical cord blood transplantation for inherited metabolic disorders. Biology of Blood and Marrow Transplantation;23:119–125.
Marty, F.M., Ljungman, P., Chemaly, R.F. et al. (2017). Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. New England Journal of Medicine; 377:2433–2444.
Matthes-Martin, S., Lion, T., Aberle, S.W. et al. (2003). Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: the impact of recipient and donor CMV serostatus on the incidence of CMV disease and CMV-related mortality. Bone Marrow Transplantation;31:803–808. 30/63.
Mayani, H., Dragowska, W. and Lansdorp, P.M. (1993). Cytokine-induced selective expansion and maturation of erythroid versus myeloid progenitors from purified cord blood precursor cells. Blood;81:3252-3258.
McCurdy, S.R., Zhang, M.J., St Martin, A. et al. (2018). Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. Blood Advances;2: 299–307.
Messer, M., Steinzen, A., Vervolgyi, E. et al. (2014). Unrelated and alternative donor allogeneic stem cell transplantation in patients with relapsed or refractory Hodgkin's lymphoma: a systematic review. Leukemia Lymphoma;55: 296–306.
Michel, G., Galambrun, C., Sirvent, A, et al. (2016). Single- vs double-unit cord blood transplantation for children and young adults with acute leukemia or myelodysplastic syndrome. Blood;127:3450-3457.
Moore, T., Sacher, M.D., Perumbeti, A.et al. (2021). Haematopoietic Stem Cell Transplantation (HSCT).http//www.emedicine.medscape.com.
Muhsen, I.N., Hashmi, S.K, Niederwieser, D. et al. (2020). The role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries. Bone Marrow Transplant; 55:698–707.
Nagler, A., Labopin, M., Dholaria, B. et al. (2021). Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia. Clinical Cancer Research; 27(3):843-851.
National Marrow Donor Program. Unrelated donor search process, step by step. Minneapolis, MN: National Marrow Donor Program; (2009).
35/16. Navarrete, C. and Contreras, M. (2009). Cord blood banking: a historical perspective. British Journal of Haematology; 147:236–245.
Niederwieser, D., Baldomero, H., Szer, J.et al. (2016). Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplantation;51: 778–785.
Nunes, E., Heslop, H., Fernandez-Vina, M. et al. (2011). Definitions of histocompatibility typing terms. Blood; 118 (23):180-183.
O’Brien, S.G., Guilhot, F., Larson, R.A. et al. (2003). Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New England Journal of Medicine;348: 994- 1004.
O’Dwyer, M.E., Mauro, M.J., Blasdel, C.et al. (2004). Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood; 103:451-455.
Pagliuca, S., Ruggeri, A. and Peffault de Latour, R. (2019). Cord blood transplantation for bone marrow failure syndromes: state of art. Stem Cell Investigation;6: 39.
Passweg, J.R., Baldomero, H., Chabannon, C. et al. (2021). Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant. https://doi.org/10.1038/s41409-021-01227-8.
Passweg, J.R., Baldomero, H., Basak, G.W. et al. (2018). The EBMT activity survey report 2017: a focus on allogeneic HCT for non-malignant indications and on the use of non-HCT cell therapies. Bone Marrow Transplant. https://doi.org/10.1038/s41409-019-0465-9.
Passweg, J.R., Baldomero, H., Bader, P. et al. (2018). Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant; 53:1139–1148.
Passweg, J.R., Baldomero, H., Bader, P. et al. (2017). Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant; 52:811–817.
Passweg, J.R., Baldomero, H., Bader, P. et al. (2016). Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. Bone Marrow Transplant; 51:786–792.
Passweg, J.R., Baldomero, H., Bader, P. et al. (2015). Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. Bone Marrow Transplant; 50:476–482.
Peffault de Latour, R., Brunstein, C.G., Porcher, R. et al. (2013). Similar overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia. Biology of Blood and Marrow Transplantation;19:1355–1360.
Peled, T., Shoham, H., Aschengrau, D, et al. (2012). Nicotinamide, a SIRT1 inhibitor, inhibits differentiation and facilitates expansion of hematopoietic progenitor cells with enhanced bone marrow homing and engraftment. Experimental Hematology;40:342-355.
Peled, T., Mandel, J., Goudsmid, R.N, et al. (2004). Pre-clinical development of cord blood-derived progenitor cell graft expanded ex vivo with cytokines and the polyamine copper chelator tetraethylenepentamine. Cytotherapy;6:244-255.
Phelan, R., Arora, M. and Chen, M. (2020). Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slidess. www.cibmtr.org.
Raiola, A.M., Risitano, A., Sacchi, N. et al. (2018). Impact of HLA disparity in haploidentical bone marrow transplantation followed by high-dose cyclophosphamide. Biology of Blood and Marrow Transplantat;24:119–126.
Raiola, A.M., Dominietto, A., Ghiso, A. et al. (2013). Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biology of Blood and Marrow Transplantation;19:117–122.
Robinson, T.M., Fuchs, E.J., Zhang, M.J. et al. (2018). Related donor transplants: has post-transplantation cyclophosphamide nullified the detrimental effect of HLA mismatch? Blood Advances;2:1180–1186.
Rocha, V., Crotta, A., Ruggeri, A. et al. (2010). Double cord blood transplantation: extending the use of unrelated umbilical cord blood cells for patients with hematological diseases. Best Practice and Research Clinical Haematoogyl;23: 223-229.
Ruggeri, A. (2019). Optimizing cord blood selection. Hematology American Society of Hematology Education Program;522–531.
Ruggeri, A., Paviglianiti, A., Gluckman, E. et al. (2016). Impact of HLA in cord blood transplantation outcomes. HLA.87:413–421.
Ruggeri, L., Capanni, M., Urbani, E. et al. (2002). Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science;295:2097–2100.
Ruggeri, L., Capanni, M., Casucci, M. et al. (1999). Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood;94:333–339.
Russo, A., Oliveira, G., Berglund, S.et al. (2018). NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. Blood ;131:247–262.
Santoro, N., Labopin, M., Giannotti, F.et al. (2018). Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT. Journal Hematolology Oncology;11:55.
Sarina, B., Castagna, L., Farina, L. et al. (2010). Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood;115: 3671–3677.
Savani, B.N., Mielke, S., Adams, S. et al. (2007). Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia;21:2145–52.
Schmitz, N., Nickelsen, M., Altmann, B. et al. (2015). Allogeneic or autologous transplantation as first-line therapy for younger patients with peripheral T-cell lymphoma: results of the interim analysis of the AATT trial. Journal of Clinical Oncology;33(15):8507–8507.
Schmitz, N., Pfistner, B., Sextro, M., Sieber, M. et al. (2002). Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. ;359:2065–2071.
Scholl, S., Klink, A., Mugge, L.O. et al. (2005). Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch. Transfusion;45:1676–1683.
Shah, N., Callander, N., Ganguly, S, et al. (2015). Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. Biology Blood Marrow Transplant; 21(7):1155-1166.
Sharma, P., Purev, E., Haverkos, B. et al. (2020). Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant. Blood Advances;4: 2227-2235.
Shpall, E.J., Quinones, R., Giller, R, et al. (2002). Transplantation of ex vivo expanded cord blood. Biology of Bone Marrow Transplantation;8:368-376.
Sideri, A., Neokleous, N., Brunet De La Grange, P. et al. (2011). An overview of the progress on double umbilical cord blood transplantation. Haematologica;96:1213-1220.
Sidlik-Muskatel, R. and Reisner, Y. (2019). Toward safer haploidnetical hematopoietic stem cell transplantation. Bone Marrow Transplant; 54:733–737.
Sirinoglu, D.I.,Ekgunduz, E., Altuntas, F. et al. (2012). What is the most appropriate source for hematopoietic stem cell transplantation? Peripheral stem cell/bone marrow/cord blood. Bone Marrow Research;834040.
Smith, A.R. and Wagner, J.E. (2009). Alternative haematopoietic stem cell sources for transplantation: place of umbilical cord blood. Br J Haematologica;147:246–261.
Solomon, S.R., Aubrey, M.T., Zhang, X. et al. (2018). Selecting the best donor for haploidentical transplant: impact of HLA, killer cell immunoglobulin-like receptor genotyping, and other clinical variables. Biology of Blood and Marrow Transplantation;24:789–798.
Spees, L.P., Martin, P.L., Kurtzberg, J. et al. (2019). Reduction in mortality after umbilical cord blood transplantation in children over a 20-year period (1995-2014). Biology of Blood and Marrow Transplantation; 25:756–763.
Spellman S, Bray R, Rosen-Bronson S, Haagenson M, Klein J, Flesch S, et al. The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. Blood. 2010;115:2704–8.
Stern, M., Brand, R., de Witte, T. et al. (2008). Female-versus-male alloreactivity as a model for minor histocompatibility antigens in hematopoietic stem cell transplantation. American Journal of Transplantation;8:2149–2157.
Stiff, P.J., Montesinos, P., Peled, T. et al. (2018). Cohort-Controlled comparison of umbilical cord blood transplantation using carlecortemcel-l, a single progenitor-enriched cord blood, to double cord blood unit transplantation. Biology of Blood and Marrow Transplantation;24:1463–1470.
Stübig, T., Alchalby, H., Ditschkowski, M. et al. (2014). JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. Leukemia. 28:1736–1738.
Stussi, G., Muntwyler, J., Passweg, J.R.et al. (2002). Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation;30: 87–93.
Sun, Y.Q., Han, T.T., Wang, Y. et al. (2021). Haploidentical stem cell transplantation with a novel conditioning regimen in older patients: a prospective single‑arm phase 2 study. Frontiers in Oncology;11:639502.
Sureda, A., Canals, C., Arranz, R. et al. (2012). Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin'slymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante deMedula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica;97:310–317.
Tomblyn, M.B., Arora, M., Baker, K.S. et al. (2009). Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome. Journal of Clinical Oncology;27:3634–3641.
Tong, J., Xuan, L., Sun, Y. et al. (2017). Umbilical cord blood transplantation without antithymocyte globulin results in similar survival but better quality of life compared with unrelated peripheral blood stem cell transplantation for the treatment of acute leukemia-a retrospective study in China. Biology of Blood and Marrow Transplantation;23: 1541-1548.
Trautinger, F., Eder, J., Assaf, C. et al. (2017). European Organization for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - update 2017. European Journal of Cancer;77: 57–74.
van Besien, K., Koshy, N., Gergis, U. et al. (2017). Cord blood chimerism and relapse after haplo-cord transplantation. Leukemia Lymphoma; 58:288–297.
Vander Lugt, M.T., Chen, X., Escolar, M.L. et al. (2020). Reduced-intensity single-unit unrelated cord blood transplant with optional immune boost for nonmalignant disorders. Blood Advances 4:3041–3052.
Vannucchi, A.M., Lasho, T.L., Guglielmelli, P. et al. (2013). Mutations and prognosis in primary myelofibrosis. Leukemia;27:1861–1869.
van Rood, J.J., Loberiza, F.R. Jr., Zhang, M.J.et al. (2002). Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling. Blood;99:1572–1577.
Wagner, J.E Jr., Brunstein, C.G., Boitano, A.E. et al. (2016). Phase I/II trial of stemregenin-1 expanded umbilical cord blood hematopoietic stem cells supports testing as a stand-alone graft. Cell Stem Cell ;18:144–155.
Wagner, J.E Jr., Eapen, M., Carter, S, et al. (2014). One-unit versus two-unit cord-blood transplantation for hematologic cancers. New England Journal of Medicine;371:1685-1694.
Wang, Y., Liu, Q‑F., Lin, R. et al. (2021). Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long‑term follow‑up of a multicenter, randomized controlled trial. Sci. Bull.
Wang, L., Devillier, R., Wan, M. et al. (2019).Clinical outcome of FLAG‑IDA chemotherapy sequential with Flu‑Bu3 conditioning regimen in patients with refrac‑ tory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli‑Calmettes. Bone Marrow Transplant ;54:458–464.
Wang, Y., Wang, H.X., Lai, Y.R. et al. (2016). Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant. Leukemia;30:2055–2063.
Wang, Y., Liu, Q.F, Xu, L.P.et al. (2016). Haploidentical versus Matched-Sibling Transplant in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia:A Biologically Phase III Randomized Study. Clinical Cancer Reserach;22:3467–3476.
Wang, Y., Liu, Q.F., Xu, L.P. et al. (2015). Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood; 125:3956–3962.
Wang, Y., Chang, Y.J, Xu, L.P. et al. (2014). Who is the best donor for a related HLA haplotype-mismatched transplant? Blood;124:843–850.
Whittaker, S.J., Marsden, J.R., Spittle, M. et al. (2003). Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Groups guidelines for the management of primary cutaneous T-cell lymphomas. British Journal of Dermatology;149: 1095–107.
Wildes, T.M., M.D., Stirewalt, D.L. et al. (2014). Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Older Adults: Geriatric Principles in the Transplant Clinic. Journal of National Cancer Network; 12(1): 128–136.
Worel, N., Shaw, B.E., Aljurf, M. et al (2021). Changes in hematopoietic cell transplantation practices in response to COVID-19: a survey from the Worldwide Network for Blood & Marrow Transplantation. Transplant Cell Therapy; 27:270–271.
Worldwide Network for Blood and Marrow Transplantation. WBMT (2016). Survey Slides. 2020. https://www.wbmt.org/.
Xu, L-P., Lu, P-H., Wu,D-P. (2021). Haematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group. Bone Marrow Transplantation; 1-8.
Yanada, M., Konuma, T., Kuwatsuka, Y. et al. (2019). Unit selection for umbilical cord blood transplantation for adults with acute myeloid leukemia in complete remission: a Japanese experience. Bone Marrow Transplantation;54: 1789–1798.
Yanada, M., Matsuo, K., Suzuki, T. et al. (2006). Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis. Cancer; 106(12):2657-2663.
Yoshihara, S., Maruya, E., Taniguchi, K.et al. (2012). Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transplantation;47: 508–515.
Yu, S., Huang, F., Wang, Y. et al. (2020). Haploidentical transplantation might have superior graft‑versus‑leuke‑ mia effect than HLA‑matched sibling transplantation for high‑risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study. Leukemia ;34:1433–1443.
Yu, S., Huang, F., Fan, Z. et al. (2020). Haploidentical versus HLA‑matched sibling transplantation for refractory acute leukemia undergoing sequential intensified condition‑ ing followed by DLI: an analysis from two prospective data. Journal of Hematology and Oncology;13:18.
Zhang, X., Chen, J., Han, M-Z. et al. (2021). The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: Journal of Haematology and Oncology; 14:145.
Zhang, Y.Y. and Mo, W.J. (2020). Comparable survival outcome between transplantation from haploidentical donor and matched related donor or unrelated donor for severe aplastic anemia patients aged 40 years and older: a retrospective multicenter cohort study. Clinical Transplantation;34:e13810.
Zhang, R., Shi, W., Wang, H. et al. (2017). Idarubicin‑intensified haploidentical HSCT with GvHD prophylaxis of ATG and basiliximab provides comparable results to sibling donors in high‑risk acute leukemia. Bone Marrow Transplant;52:1253–60.
Zhang, Y.Y., Liu, D.H., Liu, K.Y. et al. (2014). HLA-haploidentical hematopoietic SCT from collateral related donors without in vitro T-cell depletion for hematological malignancies. Bone Marrow Transplantation;49: 496–501.
Zhang, C., Chen, X.H., Zhang, X. et al. (2010). Stem cell collection in unmanipulated HLA-haploidentical/mismatched related transplantation with combined granulocyte-colony stimulating factor-mobilised blood and bone marrow for patients with haematologic malignancies: the impact of donor characteristics and procedural settings. Transfusion Medicine. ;20:169–177.
Zheng, F.M., Zhang, X., Li, C.F. et al. (2020). Haploidentical‑ versus identical‑sibling transplaer nt for high‑risk pedi‑atric AML: a multi‑centstudy. Cancer Commun (Lond);40:93–104.
Zheng, C.C., Zhu, X.Y., Tang, B.L, et al. (2018). Double vs. single cord blood transplantation in adolescent and adult hematological malignancies with heavier body weight (≥50 kg). Hematology;23:96-104.
Zheng, C.C., Zhu, X.Y., Tang, B.L. et al. (2017). Clinical separation of cGvHD and GvL and better GvHD free/relapse-free survival (GRFS) after unrelated cord blood transplantation for AML. Bone Marrow Transplant;52: 88-94.
Zheng, X. and Tian, Z. (2021). Which is better, HLA-matched sibling or haploidentical transplantation?. Cellular and Moleculer Immunology;18: 1347.
Zhou, W., Longmate, J., Lacey, S.F.et al. (2009). Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV positive transplant recipients. Blood;113: 6465–6476.
Zhu, X., Tang, B. and Sun, Z. (2021). Umbilical cord blood transplantation: Still growing and improving. Stem cells translational medicine;10: 562-574.